Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278031 | 0.93 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL6685103 | 0.86 | ESR1 (0.74) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL28848601 | 0.84 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL11577478 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL5873468 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL8851612 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL9479412 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL3011129 | 0.80 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| Chlorphentermine SCHEMBL160516 | 0.80 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL11670635 | 0.78 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | MERCK SHARP & DOHME LLC | 2007-04-26 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5965613-A | FUNGICIDES FOR USE IN AGRICULTURE AND HORTICULTURE; THE COMPOUNDS ALSO HAVE INSECTICIDAL AND ACARICIDAL ACTIVITY | NOVARTIS FINANCE CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-4853489-A | TO PARA-TERTIARY-BUTYLBENZYL CHLORIDE; | GIVAUDAN CORPORATION | 1989-08-01 | — | — | US | disclosed |
| US-4808568-A | AZOPYRIDONE YELLOW DYE COATING ON SHEET; BRIGHTNESS, LIGHTFASTNESS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | SLC6A4 3148/4885SLC6A2 4544/4885SLC6A3 4498/4885 |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | GPR119, GLP1R, INSR | SLC6A4 4253/4885SLC6A2 4281/4885SLC6A3 4509/4885 |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | SLC6A4 3074/4885SLC6A2 3554/4885SLC6A3 2758/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | SLC6A4 3410/4885SLC6A2 2958/4885SLC6A3 2530/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | SLC6A4 2479/4885SLC6A2 1160/4885SLC6A3 2113/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | SLC6A4 4877/4885SLC6A2 4884/4885SLC6A3 4879/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | SLC6A4 4681/4885SLC6A2 4471/4885SLC6A3 2594/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | SLC6A4 2336/4885SLC6A2 3588/4885SLC6A3 2277/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | SLC6A4 3218/4885SLC6A2 3667/4885SLC6A3 2773/4885 |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | ZC3HAV1, COPB1, CNBP | SLC6A4 4713/4885SLC6A2 4766/4885SLC6A3 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.